What is the recommended first-line therapy for invasive aspergillosis, including dosing, alternatives for contraindications, and management of allergic bronchopulmonary aspergillosis?

Aspergillosis Treatment Recommendations

Invasive Aspergillosis: First-Line Therapy

Voriconazole is the recommended first-line treatment for invasive pulmonary aspergillosis based on strong evidence from multiple international guidelines. 1, 2, 3

Voriconazole Dosing

Loading dose: 6 mg/kg IV every 12 hours for 2 doses (day 1)

Maintenance dose: 4 mg/kg IV every 12 hours, or switch to oral 200-300 mg every 12 hours once stable 2

Pediatric dosing: 5-7 mg/kg IV every 12 hours (higher than adults due to pharmacokinetic differences) 1

Critical considerations:

• Higher dosages are needed for Aspergillus flavus and Aspergillus terreus compared to Aspergillus fumigatus 3
• Therapeutic drug monitoring is essential for dose adjustment 3
• Be aware of significant drug interactions, particularly with anticonvulsants in CNS aspergillosis 3

Alternative First-Line Agents (When Voriconazole Contraindicated)

Liposomal amphotericin B: 3-5 mg/kg IV daily 1, 2, 3

• Use when triazoles are contraindicated, not tolerated, or in regions with high azole resistance 3
• Preferred in CNS aspergillosis as alternative to voriconazole 3

Isavuconazole: 200 mg every 8 hours for 6 doses (loading), then 200 mg daily 2

• Newer option with similar efficacy to voriconazole but better tolerability profile 4
• Fewer drug interactions and adverse events compared to voriconazole 4

Salvage/Alternative Therapy Options

When primary therapy fails or is not tolerated:

• Posaconazole (multiple formulations with different dosing):

  • Oral suspension: 200 mg QID initially, then 400 mg BID after stabilization (take with fatty food) 3
  • Delayed-release tablets: 300 mg BID day 1, then 300 mg daily 3
  • IV formulation: 300 mg BID day 1, then 300 mg daily 3

• Echinocandins (not recommended as primary monotherapy but effective for salvage):

  • Caspofungin: 70 mg IV day 1, then 50 mg IV daily 1, 2
  • Micafungin: 100-150 mg IV daily 3
  • Anidulafungin: 200 mg IV day 1, then 100 mg IV daily 3

• Amphotericin B lipid complex (ABLC): 5 mg/kg IV daily 1, 2

Duration of Therapy

Treat for minimum 6-12 weeks, continuing until:

• Resolution or stabilization of all clinical manifestations
• Resolution or stabilization of radiographic findings
• Reversal of immunosuppression (if feasible) 1, 3

Longer duration required for:

• Osteomyelitis or other deep-seated infections
• Persistent immunosuppression
• Extensive disease 1

Combination Therapy

Primary combination therapy (voriconazole + echinocandin) is NOT routinely recommended based on lack of definitive clinical benefit 1, 2, 3. The 2025 ATS guideline provides only a conditional recommendation for either combination or monotherapy, acknowledging low-quality evidence 5.

Consider combination therapy in:

• Salvage situations with treatment failure
• Selected patients with proven/probable invasive aspergillosis and severe disease 3
• CNS aspergillosis (case-by-case basis) 3

Site-Specific Considerations

CNS aspergillosis: Voriconazole preferred (excellent CNS penetration); liposomal amphotericin B as alternative. Surgical resection if feasible 3

Endocarditis: Voriconazole or liposomal amphotericin B PLUS early surgical intervention mandatory to prevent embolic complications. Lifelong antifungal therapy post-operatively 3

Invasive sinonasal aspergillosis: Same as pulmonary, but consider initial polyene therapy if mucormycosis cannot be excluded. Surgical debridement as adjunct 3

---

Allergic Bronchopulmonary Aspergillosis (ABPA)

Oral corticosteroids remain the cornerstone of acute ABPA therapy, with itraconazole providing important corticosteroid-sparing effects. 1, 6

First-Line Treatment

Oral corticosteroids:

• Prednisolone 0.5 mg/kg/day for 2 weeks, then 0.5 mg/kg every other day for 8 weeks, then taper by 5 mg every 2 weeks over 3-5 months 6
• Alternative regimen: 0.5,0.25, and 0.125 mg/kg/day for 4 weeks each, then taper 6

Itraconazole (steroid-sparing agent):

• Conventional capsules: 400 mg/day in two divided doses for 4 months (maximum 600 mg/day), taken with meals 6
• Super bioavailable capsules: 260 mg/day in two divided doses for 4 months (maximum 390 mg/day), taken on empty stomach 6
• Has demonstrable corticosteroid-sparing effect based on RCT evidence 1, 6

Alternative Antifungal Agents

When itraconazole is not tolerated or contraindicated:

• Voriconazole: 200 mg PO every 12 hours, taken on empty stomach 1, 6
• Posaconazole: 400 mg PO BID (suspension with fatty meals) or 300 mg daily (delayed-release tablet with meals) 1, 6
• Isavuconazole: 200 mg daily (emerging option with case report evidence) 7

Biological Agents (Treatment-Dependent ABPA)

For patients requiring frequent corticosteroid courses or unable to taper steroids:

• Omalizumab: Reduces asthma exacerbations and has steroid-sparing action (Level II evidence) 6
• Other biologics (mepolizumab, benralizumab, dupilumab, tezepelumab): Emerging evidence for steroid-sparing effects (Level III evidence) 6

Adjunctive Therapy

Nebulized amphotericin B: May reduce ABPA exacerbations and increase time-to-first exacerbation when used as maintenance therapy in stable ABPA (Level II evidence) 6

• Amphotericin B deoxycholate: 10 mg twice daily, 3-6 times per week 6
• Liposomal amphotericin B: 25-50 mg once or twice weekly 6

Duration

Antifungal therapy typically continued for 3-6 months 6, 8

Important Caveats

• High-dose inhaled corticosteroids alone do NOT achieve adequate symptom control or reduce exacerbations as primary therapy 6
• Oral antifungals have similar efficacy to systemic glucocorticoids with fewer adverse events 6
• Monitor for progression to invasive disease, particularly in patients on systemic corticosteroids 8